Literature DB >> 7153870

Rapid and slow release phenytoin in epileptic patients at steady state: comparative plasma levels and toxicity.

R J Sawchuk, S M Pepin, I E Leppik, R J Gumnit.   

Abstract

Phenytoin plasma level and toxicity data were compared in a three-way crossover study performed in 18 patients at steady state. Formulations compared were a rapid and a slow release capsule and an oral solution. Plasma concentration-time integrals and maximum plasma phenytoin levels were significantly greater for the rapid release capsule and solution than for the slow release capsule. The incidence of nystagmus and toxicity did not differ for the three treatments, but the occurrence of mental symptoms was more frequent for the oral solution, possibly because of the solvent used in this formulation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7153870     DOI: 10.1007/bf01065169

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  4 in total

1.  Time to reach steady state and prediction of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1978-06

2.  Liquid-chromatographic method for simultaneous determination of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in plasma and urine.

Authors:  R J Sawchuk; L L Cartier
Journal:  Clin Chem       Date:  1980-06       Impact factor: 8.327

3.  Rate of phenytoin accumulation in man: a simulation study.

Authors:  T M Ludden; J P Allen; L W Schneider; S A Stavchansky
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

4.  Steady-state plasma concentrations as a function of the absorption rate and dosing interval for drugs exhibiting concentration-dependent clearance: consequences for phenytoin therapy.

Authors:  R J Sawchuk; T S Rector
Journal:  J Pharmacokinet Biopharm       Date:  1979-12
  4 in total
  4 in total

Review 1.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

2.  Computer-aided dosage form design. III. Feasibility assessment for an oral prolonged-release phenytoin product.

Authors:  J R Irvin; R E Notari
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

3.  Rapid and slow release phenytoin in epileptic patients at steady state: assessment of relative bioavailability utilizing Michaelis-Menten parameters.

Authors:  R J Sawchuk; S M Pepin; I E Leppik; R J Gumnit
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

4.  Pharmacokinetics of propylene glycol in the rabbit.

Authors:  D K Yu; R J Sawchuk
Journal:  J Pharmacokinet Biopharm       Date:  1987-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.